These data indicate that, given the difficulty of collecting biopsy samples in NASH and AH patients, development of RIP1, RIP3, and MLKL as a panel of less-invasive circulating biomarkers for NASH and AH may address an important unmet clinical need (54). Here, MLKL is linked to metabolic dysfunction-associated steatohepatitis.